# Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

> **NCT00450086** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 92 (actual)

## Conditions studied

- Collagenous Colitis

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Mesalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00450086
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-08
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450086, "Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00450086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*